Identify and Validate Molecular Targets for Therapy in a Newly Developed Human Midgut Carcinoid Tumor Cell Line
Researcher: Lee Ellis, MD Location: MD Anderson Cancer Center State: Texas Year: 2006 Status: Finished
Leave it blank
To identify and validate molecular targets for therapy in a newly developed human midgut carcinoid tumor cell line as well as validate other neuroendocrine tumor cell lines.
The overall goal of this proposal is to identify and validate molecular targets for therapy in a newly developed human midgut carcinoid tumor cell line.
Utilizing a newly established cell line (there are only 2 in the world), we will determine proteins that mediate tumor growth by standard molecular biologic techniques. Once these targets are identified, we will use combinations of targeted therapies to inhibit growth in a novel model of liver metastasis in mice. We will also establish new cell lines, as we have a large clinical practice treating patients with carcinoid tumors. Identification of molecular targets will allow for the rapid development of new therapies to be tested in subsequent years in clinical trials by Dr. James Yao and colleagues.
Research Progress and Results:
Attempted to create neuroendocrine cell lines.
Funding from the CFCF supported Lee Ellis’s work that provided a new cell line for study by numerous labs around the world. Initial studies identified new targets for therapy that can be tested in clinical trials. CFCF funding supported the first study reporting on cancer stem cells in carcinoid tumors. Cancer stem cells are thought to be the originating cells in cancers that mediate resistance to therapies and metastasis.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116